About EXESALIBERO PHARMA, INC
ExesaLibero Pharma is dedicated to developing new small molecule drugs to treat bone disease, focusing on preclinical toxicology and efficacy studies for a groundbreaking drug targeting bone erosion in conditions like rheumatoid arthritis, multiple myeloma, diabetes, periodontal disease, and tuberculosis.
Development of small molecule drugs for bone diseasePreclinical toxicology and efficacy studiesInvestigative New Drug (IND) application preparationClinical trial initiation following FDA approvalResearch on ion-channel antagonists to suppress osteoclast maturation
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to EXESALIBERO PHARMA, INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.